The American Lung Association proudly honors Eli Lilly for their Oncology Excellence. Their leadership in oncology and lung cancer innovation highlights the company's commitment to developing therapies that improve outcomes for patients with lung cancer. 

 

Through scientific excellence, investment in groundbreaking research, and a focus on addressing unmet patient needs, Eli Lilly continues to drive progress in cancer care. Their work in lung cancer has brought new hope to patients and families facing a difficult diagnosis and underscores its commitment to improving survival, quality of life, and the future of oncology treatment.